+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07214532

Evaluation of ctDNA-Guided CDK46 Inhibitor Therapy Initiation in Intermediate-Risk HRHER2- Early-Stage Breast Cancer

Led by Natera, Inc. · Updated on 2026-09-23

725

Participants Needed

49

Research Sites

293 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of using circulating tumor DNA ctDNA testing with the Signatera Genome assay to guide the start of CDK46 inhibitor therapy in participants with intermediate-risk, early-stage hormone receptor-positive HR, HER2-negative breast cancer. This approach aims to determine if starting CDK46 inhibitors based on ctDNA results can maintain treatment effectiveness while reducing unnecessary medication use, comparing outcomes to historical data from the NataLEE trial. Participants will undergo ctDNA testing every three months for up to four years. Those testing positive for ctDNA at baseline or during surveillance will start CDK46 inhibitor therapy either ribociclib or abemaciclib combined with hormone therapy for at least two years. Participants who remain ctDNA negative will continue hormone therapy alone with ongoing ctDNA monitoring. Treatment choices follow standard care guidelines and continue until disease progression, unacceptable side effects, or study end. During the study, participants will have regular blood draws for ctDNA testing, hormone therapy, and imaging as needed. Researchers will monitor invasive disease-free survival for up to nine years after surgery. Quality of life assessments and ongoing safety monitoring are part of the follow-up, which will last up to nine years to fully assess cancer outcomes and compare with historical controls.

CONDITIONS

Brief Title

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Research Team

C

Chelsea Nihill, MS

J

Jessica Reyes, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here